Jean Marc Sabaté

Prof. Jean Marc Sabaté

Assistance Publique Hopitaux Paris (APHP),Gastroenterol Dept, Avicenne Hospital, Bobigny, France
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2016 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
Jean Marc SabatéJean Marc Sabaté
Jean Marc Sabaté
MCMuriel Coupaye
Muriel Coupaye
SLSéverine Ledoux
Séverine Ledoux
BCBenjamin Castel
Benjamin Castel
SMSimon Msika
Simon Msika
PJPauline Jouet
Pauline Jouet

7 September 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
CBCamille Buscail
Camille Buscail
Jean Marc SabatéJean Marc Sabaté
Jean Marc Sabaté
MBMichel Bouchoucha
Michel Bouchoucha
EEmmanuelle Kesse-Guyot
Emmanuelle Kesse-Guyot
SHSerge Hercberg
Serge Hercberg
CJChantal Julia
Chantal Julia
Background: Diet appears to play a key role in the pathogenesis of the irritable bowel syndrome (IBS). Some dietary patterns (DP) could increase the risk of triggering or worsening IBS symptoms. This cross-sectional study aimed to assess the association between a posteriori derived DP and IBS in a large French population, the web-based NutriNet-Santé cohort. Methods: Study population included participants of the NutriNet-Santé study who completed a questionnaire based on Rome III criteria assessing IBS. A principal component analysis (PCA) was performed to identify major DPs based on 29 food groups’ consumption. Associations between DP quintiles and IBS were investigated with multivariable logistic regressions. Results: 44,350 participants were included, with 2423 (5.5%) presenting IBS. Three major DP were extracted using PCA, “healthy,” “western,” and “traditional.” After adjustments on confounders, the “western” DP was positively associated with IBS (OR Q5 vs. Q1 = 1.38, 95% CI 1.19–1.61, p trend < 0.0001) and the “traditional” DP was positively associated with IBS in women (OR Q5 vs. Q1 = 1.29 95% CI 1.08–1.54, p trend = 0.001). Conclusions: In this study, a “western” DP—highly correlated with the consumption of fatty and sugary products and snacks—was associated with a moderate increased risk of IBS.

21 February 2022 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Jean Marc SabatéJean Marc Sabaté
Jean Marc Sabaté
FIFranck Iglicki
Franck Iglicki
Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome

1 September 2021 in Ethics, Medicine and Public Health
Verified
Journal Article
Closed access
Jean Marc SabatéJean Marc Sabaté
Jean Marc Sabaté
DDD. Deutsch
D. Deutsch
Chloé MelchiorChloé Melchior
Chloé Melchior
AEA. Entremont
A. Entremont
FMF. Mion
F. Mion
PJP. Jouët
P. Jouët

13 June 2021 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
Antoine LemaireAntoine Lemaire
Antoine Lemaire
YPYoann Pointreau
Yoann Pointreau
BNBérengère Narciso
Bérengère Narciso
FPFrançois-Xavier Piloquet
François-Xavier Piloquet
VBViorica Braniste
Viorica Braniste
Jean Marc SabatéJean Marc Sabaté
Jean Marc Sabaté
Purpose: Naloxegol, an oral once-daily peripherally acting mu-opioid receptor antagonist, is indicated for the treatment of opioid-induced constipation (OIC) with inadequate response to laxative(s), in cancer and non-cancer patients. This study mainly aimed to assess in real-life conditions the efficacy and safety of naloxegol in cancer pain patients and the evolution of their quality of life. Methods: A non-interventional, 4-week follow-up study was conducted in 24 French oncology and pain centers between 2018 and 2019. Eligible patients were aged ≥ 18 years, treated with opioids for cancer pain, and started naloxegol for OIC with inadequate response to laxatives. The rate of the response to naloxegol (primary criterion) was assessed at W4. The evolution of quality of life was measured using the Patient Assessment of Constipation Quality of Life (PAC-QOL). Results: A total of 124 patients were included (mean age, 62 ± 12 years; ECOG ≤ 2, 79%; primary cancer, lung 18%, breast 16%, prostate 11%, head and neck 9%, digestive 9%…; metastatic stage, 80%). At inclusion, the median opioid dosage was 60 mg of oral morphine or equivalent. At W4, the response rate was 73.4% (95% CI [63.7–83.2%]), and 62.9% (95% CI [51.5–74.2%]) of patients had a clinically relevant change in quality of life (decrease in PAC-QOL score ≥ 0.5 point). Adverse events related to naloxegol were reported in 8% of patients (7% with gastrointestinal events; one serious diarrhea). Conclusion: This real-world study shows that naloxegol is effective and well tolerated in cancer pain patients with OIC and that their quality of life improves under treatment.

12 May 2020 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
AKAKOI KOIVOGUI
AKOI KOIVOGUI
SLShai Levi
Shai Levi
MFMaya Finkler
Maya Finkler
SLShlomo Lewkowicz
Shlomo Lewkowicz
TGThierry Gombeaud
Thierry Gombeaud
RBRobert Benamouzig
Robert Benamouzig